simvastatin + zoledronic acid + bortezomib + bendamustine + methylprednisolone

This is a multi-agent combination regimen consisting of five drugs, each with distinct mechanisms of action and therapeutic roles, primarily used in the treatment of hematologic malignancies such as multiple myeloma and lymphomas. - **Simvastatin** is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis. It may also have pleiotropic effects including anti-inflammatory and potential antitumor properties. - **Zoledronic acid** is a bisphosphonate that inhibits osteoclast-mediated bone resorption, commonly used to prevent skeletal-related events in cancers with bone involvement. - **Bortezomib** is a proteasome inhibitor that disrupts protein degradation pathways, leading to apoptosis in malignant plasma cells; it is widely used for multiple myeloma therapy. - **Bendamustine** is an alkylating agent with unique structural features combining properties of both alkylators and purine analogs; it induces DNA crosslinking resulting in cell death[4][6][7]. It has demonstrated efficacy as monotherapy or in combination regimens for chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma[5][6][7]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive effects; it also induces apoptosis in certain hematologic malignancies. This specific five-drug combination does not correspond to any single branded regimen but represents an intensive protocol likely designed for aggressive or refractory disease settings where synergistic cytotoxicity from different drug classes may be beneficial.